NexLife pharmacy: 503A, 503B and what we could verify
As of October 15, 2026, NexLife's standard plan pages say prescriptions are filled by three state-licensed 503A compounding pharmacies: Absolute Pharmacy in Lutz, Florida, Premium Compounding in Decatur, Alabama, and Boudreaux's New Drug Store in Lake Charles, Louisiana.
Other NexLife pages mention unnamed 503B outsourcing facilities and a wider pharmacy list; we have not independently verified any pharmacy's licence.
503A and 503B in one table
| Entity | What it is | In NexLife's case |
|---|---|---|
| Telehealth platform | Arranges the visit and the prescription | NexLife (prescribing through Nexlife Medical Group P.C.; medical director Adam Kennah, M.D.) |
| 503A pharmacy | State-licensed; compounds for an individual patient's prescription | Three named on the standard plan pages |
| 503B outsourcing facility | Registered with FDA; may compound without patient-specific prescriptions; must follow CGMP | Mentioned on the FAQ and some program pages; none named |
| Manufacturer | Makes the FDA-approved drug | Not involved; compounded drugs are not FDA-approved |
Neither status makes a compounded drug FDA-approved. Our 503A vs 503B explainer covers the legal differences in more depth.
What each NexLife page says
| NexLife page | What it says about pharmacies | Read |
|---|---|---|
| Tirzepatide and semaglutide all-plans pages | Filled by Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA); “state-licensed 503A compounding pharmacies” | Oct 15, 2026 |
| Site-wide FAQ | “Certain formulations are sourced from FDA-registered 503B outsourcing facilities ... while others may be fulfilled by licensed 503A pharmacies”; no facility named | Oct 15, 2026 |
| Microdose semaglutide page | May be fulfilled by “U.S.-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities” | Oct 15, 2026 |
| Sublingual ODT pages | “U.S.-licensed 503A & 503B compounding pharmacies” | Oct 15, 2026 |
| Microdose program pages | Listed Absolute, Hallandale, Red Rock, Empower and Strive “or other qualified 503A compounding pharmacies” | Sep 20, 2026 |
The standard plan pages are the most specific and the only ones that name pharmacies with locations. The other pages describe a wider, partly unnamed network. We report this as an inconsistency in NexLife's disclosures, not as evidence that any 503B facility fills NexLife prescriptions: we did not see one named.
Read the pharmacy disclosure on NexLife's plan page →
Why the difference matters in 2026
FDA's shortage-era grace periods for compounded tirzepatide and semaglutide ended in 2025. A 503A pharmacy may now compound them only for an individual patient whose prescriber documents a clinically significant difference from the approved drug. On the 503B side, FDA proposed on April 30, 2026 (91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; the comment period was extended to July 30, 2026, and no final decision had been published by October 15. That is one reason we anchor on the 503A disclosure on NexLife's plan pages, the only one that names pharmacies. See our legality page for the full picture.
The Empower warning letter
Empower is one of the pharmacies NexLife's microdose pages listed as a possible fulfilment pharmacy in September. On September 18, 2026, FDA issued warning letter 738238 to Empower Clinic Services, LLC, doing business as Empower Pharmacy, posted September 22. FDA said its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products” and cited insanitary conditions. Empower does not appear among the three pharmacies on NexLife's standard plan pages. We do not know whether Empower has filled any NexLife prescription; if you are on a microdose plan, ask.
What to ask NexLife before you start
- Which pharmacy will fill my prescription, and is it one of the three named on the plan page?
- Is that pharmacy a 503A pharmacy or a 503B outsourcing facility?
- Will the pharmacy's name and licence number appear on the label?
- Does my prescription contain anything besides tirzepatide or semaglutide, such as B12 or niacinamide?
- How will I be told if the fulfilling pharmacy changes?
You can check a pharmacy's licence on the state board of pharmacy website for Florida, Alabama or Louisiana, and an outsourcing facility on FDA's 503B registration list. Our pharmacy verification guide shows how.
NexLife · our #1 pick, with pharmacies named on its plan pages
Standard tirzepatide $169 down to $139 a month; semaglutide $139 down to $119. The plan pages name three state-licensed 503A pharmacies in Florida, Alabama and Louisiana.
- Provider review and medical guidance from NexLife Medical Group
- A personalized GLP-1 nutrition plan
- A 1:1 call with a certified wellness coach
- 24/7 customer support
- Free expedited shipping
Frequently asked questions
Does NexLife use a 503A or 503B pharmacy?
NexLife's standard plan pages say prescriptions are filled by three state-licensed 503A pharmacies: Absolute Pharmacy, Premium Compounding and Boudreaux's New Drug Store. Its FAQ and some program pages also mention 503B outsourcing facilities, but name none.
Which pharmacies does NexLife name?
As of October 15, 2026, the tirzepatide and semaglutide plan pages name Absolute Pharmacy in Lutz, Florida, Premium Compounding in Decatur, Alabama, and Boudreaux's New Drug Store in Lake Charles, Louisiana. We have not independently verified their licences.
Does NexLife use Empower Pharmacy?
NexLife's microdose pages listed Empower among possible fulfilment pharmacies when we read them on September 20, 2026. Empower is not named on the standard plan pages. FDA sent Empower a warning letter dated September 18, 2026. Ask NexLife which pharmacy fills yours.
Is a 503B pharmacy safer than a 503A pharmacy?
Not automatically. A 503B outsourcing facility registers with FDA and must follow manufacturing quality rules, while a 503A pharmacy is overseen mainly by its state board. Neither makes a compounded drug FDA-approved, and FDA has proposed keeping tirzepatide and semaglutide off the 503B bulks list.
How can I check NexLife's pharmacy?
Ask which pharmacy will fill your prescription, check that its name appears on the label, and look up its licence on that state's board of pharmacy site. For an outsourcing facility, check FDA's list of registered 503B facilities.
Ask NexLife about your pharmacy at sign-up →
Sources
- NexLife — Tirzepatide all plans (pharmacy disclosure) (read October 15, 2026)
- NexLife — Semaglutide all plans (read October 15, 2026)
- NexLife — Frequently asked questions (read October 15, 2026)
- NexLife — Microdose semaglutide program (read October 15, 2026)
- NexLife — Sublingual tirzepatide ODT (read October 15, 2026)
- FDA — Warning letter 738238 to Empower Pharmacy (letter dated September 18, 2026; read October 15, 2026)
- FDA — Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (read October 15, 2026)
- Federal Register — 91 FR 23431, 503B bulk drug substances list (May 1, 2026) (read October 15, 2026)